Skip to main content
. Author manuscript; available in PMC: 2012 Apr 7.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558–564. doi: 10.1097/QAI.0b013e3181ee3d82

TABLE 2.

Incidence of LFT Abnormalities (Without Regard to Baseline) at Week 48 and EBT

Incidence (Unadjusted), n(%)
 Incidence (Adjusted) Event Counts Adjusted to 100 Years of Patient Exposure, n (%)
Placebo + OBT MVC Every Day + OBT MVC Twice a Day + OBT Placebo + OBT MVC Every Day + OBT MVC Twice a Day + OBT
Week 48
    AST: >3.0 × ULN 17 (8) 39 (10) 45 (11) 16.2 13.8 15.7
    ALT: >3.0 × ULN 13 (6) 29 (7) 37 (9) 12.4 10.1 12.7
    Total bilirubin: >1.5 × ULN 30 (14) 66 (16) 51 (12) 31.9 25.3 18.5
EBT
    AST: >3.0 × ULN 19 (9) 45 (11) 46 (11) 13.3 9.4 9.5
    ALT: >3.0 × ULN 15 (7) 37 (9) 39 (9) 10.0 7.8 7.8
    Total bilirubin: >1.5 × ULN 31 (15) 68 (17) 54 (13) 23.8 16.0 11.3

ULN, upper limit of normal; MVC, maraviroc.

Total patient-years of exposure to study drug at week 48: placebo + OBT, 111, MVC, QD + OBT 300, MVC BID + OBT, 309. Total years of exposure to study drug at EBT: placebo + OBT, 160, MVC QD + OBT, 522, MVC BID + OBT, 551.